Arcus Biosciences (RCUS) Amortization of Deferred Charges (2020 - 2026)

Arcus Biosciences' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges changed 0.0% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $7.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $7.0 million, changed 0.0% from the prior year.
• Amortization of Deferred Charges steadied at $2.0 million in Q1 2026 per RCUS's latest filing, from $2.0 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $2.0 million in Q1 2022 and bottomed at $1.0 million in Q3 2024.
• The 5-year median for Amortization of Deferred Charges is $2.0 million (2022), against an average of $1.9 million.
• Across the five-year window, Amortization of Deferred Charges jumped 271.75% in 2022 and sank 50.0% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
• Per Business Quant, the three latest RCUS Amortization of Deferred Charges figures stand at $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025).